http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
불연속 갤러킨 유한요소법을 이용한 1차원 천수방정식의 댐 붕괴류 및 천이류 해석
윤광희,이해균,이남주,Yun, Kwang Hee,Lee, Haegyun,Lee, Namjoo 대한토목학회 2014 대한토목학회논문집 Vol.34 No.5
최근, 급속한 컴퓨터 하드웨어의 성능 향상과 전산유체역학 분야의 이론적 발전으로, 고차 정확도의 수치기법들이 계산수리학 분야에 적용되어 왔다. 본 연구에서는 1차원 천수방정식에 대한 수치 해법으로 TVD Runge-Kutta 불연속 갤러킨(RKDG) 유한요소법을 적용하였다. 대표적인 천이류(transcritical flow)의 예로 순간적인 댐 붕괴에 의한 댐 붕괴류(dam-break flow) 흐름과 지형변화에 의한 천이류를 모의하였다. 리만(Riemann) 근사해법으로 로컬 Lax-Friedrichs (LLF), Roe, HLL 흐름률(flux) 기법을 사용하였고, 불필요한 진동을 제거하기 위하여, 기울기 제한자로서 MUSCL 제한자를 사용하였다. 개발된 모델은 1차원 댐 붕괴류와 천이류에 적용하였다. 수치해석 결과는 해석해, 수리실험 결과와 비교하였다. Recently, with rapid improvement in computer hardware and theoretical development in the field of computational fluid dynamics, high-order accurate schemes also have been applied in the realm of computational hydraulics. In this study, numerical solutions of 1D shallow water equations are presented with TVD Runge-Kutta discontinuous Galerkin (RKDG) finite element method. The transcritical flows such as dam-break flows due to instant dam failure and transcritical flow with bottom elevation change were studied. As a formulation of approximate Riemann solver, the local Lax-Friedrichs (LLF), Roe, HLL flux schemes were employed and MUSCL slope limiter was used to eliminate unnecessary numerical oscillations. The developed model was applied to 1D dam break and transcritical flow. The results were compared to the exact solutions and experimental data.
윤광희(Kwang Hee Yun),박진영(Jin Young Park),박선주(Sun Joo Park),조은희(Eun Hee Cho),유제만(Jei Man Ryu),김경식(Kyung Sik Kim),정석재(Suk Jae Chung),이민화(Min Hwa Lee),심창구(Chang Koo Shim) 한국응용약물학회 1999 Biomolecules & Therapeutics(구 응용약물학회지) Vol.7 No.1
A bioequivalence study of the Dong Wha Cisapril tablets(Dong Wha Pharm. Ind. Co., Ltd.) to the Prepulsid tablets(Janssen Korea Ltd.), formulations of cisapride, was conducted. Twenty four healthy Korean male subjects received each formulation at the dose of 5 mg as cisapride in a 2 x 2 crossover study. There was a 1-week washout period between the doses. Plasma concentrations of cisapride were monitored by an LC/MS method for over a period of 36 h after each administration. AUC(area under the plasma concentrationtime curve from time zero to infinity) was calculated by the linear trapezoidal and extrapolation method. C_(max)(maximum plasma drug concentration) and T_(max)(time to reach C_(max)) were compiled from the plasma drug concentration-time data. Analysis of variance (ANOVA) revealed that there are no differences in AUC, C_(max) and T_(max) between the formulations. The apparent differences between the formulations in these parameters were all far less than 20% (i.e., 6.8, -6.6 and 1.8% for AUC, C_(max) and T_(max), respectively). Minimum detectable differences(%) at α=0.05 and 1-β=0.8 were all less than 20% in these parameters between the formulations (i.e., 16.5, 11.4 and 16.4% for AUC, C_(max) and T_(max) respectively). The 90% confidence intervals for these parameters were also within 20% (i.e., -2.9∼16.4, -13.2∼0.1 and -7.8∼11.4% for AUC, C_(max) and T_(max) respectively). These results satisfy the bioequivalence criteria of the Korea Food and Drug Administration (KFDA) guidelines (No. 98-51). Therefore, these results indicate that the two formulations of cisapride are bioequivalent and, thus, may be prescribed interchangeably.